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A B S T R A C T
Human skin maintains the ability to regenerate during adulthood, as it constantly renews itself throughout adult
life, and the hair follicle (HF) undergoes a perpetual cycle of growth and degeneration. The study of stem cells (SCs) in
the epidermis and skin tissue engineering is a rapidly emerging field, where advances have been made in both basic and
clinical research. Advances in basic science include the ability to assay SCs of the epidermis in vivo, identification of an
independent interfollicular epidermal SC, and improved ability to analyze individual SCs divisions, as well as the re-
cent hair organ regeneration via the bioengineered hair follicular unit transplantation (FUT) in mice. Advances in the
clinic include recognition of the importance of SCs for wound repair and for gene therapy in inherited skin diseases, for
example epidermolysis bullosa. The study of the HF stem cells (HFSCs) started by identification of epidermal SC in the
HF bulge as quiescent »label retaining cells«. The research of these cells emerged rapidly after the identification of bulge
cell molecular markers, such as keratin 15 (K15) and CD34 in mice and CD200 in humans, which allowed the isolation
and characterization of bulge cells from follicles. This paper provides an overview of the current knowledge on epidermal
SCs in the HF, describing their essential characteristics and the control of follicle SCs fate, their role in alopecia, as well
as their use in tissue engineering.
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Introduction
It is well accepted that human skin maintains the
ability to regenerate during adulthood, which allows it to
play the role as an interface with the external world and
to maintain vital homeostatic functions throughout life1.
The skin constantly renews itself throughout adult life,
and the hair follicle undergoes a perpetual cycle of
growth and degeneration. Adult skin is composed of a di-
verse organized array of cells deriving from different em-
bryonic origins. During development, the neurectoderm
cells form the stratified epithelium (sometimes called
interfollicular epidermis), the hair follicles (HFs), seba-
ceous glands, and, in nonhaired skin, the apocrine
(sweat) glands1. Each of these three epithelial lineages
contains its own stem cell (SC) populations, residing in
the epidermis and HF, and ensuring the maintenance of
adult skin homeostasis and hair regeneration, but also
participating in the repair of the epidermis after in-
juries2,3.
Complications of normal regeneration of the skin re-
sult in chronic wounds, excessive scarring, alopecia or
malignant transformation. As human populations prone
to inadequate skin healing (in example the aged, obese,
and diabetics) keep growing, treating the abovemen-
tioned conditions significantly contribute to the global
health burden4,5. Therefore, novel therapies to treat dys-
functional skin repair and regeneration are critical, espe-
cially for the patients suffering from extensive burns or
hereditary skin diseases6.
The study of stem cells (SCs) in the epidermis and
skin tissue engineering is a rapidly emerging field, where
advances have been made in both basic and clinical
research7. Advances in basic science include the ability to
assay stem cells of the epidermis in vivo, identification of
an independent interfollicular epidermal SCs, and im-
proved ability to analyze individual SC divisions7, as well
as the recent hair organ regeneration via the bioengi-
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neered hair follicular unit transplantation (FUT) in mi-
ce8,9. Advances in the clinic include recognition of the im-
portance of SCs for wound repair and for gene therapy in
inherited skin diseases, for example epidermolysis bullo-
sa10.
This paper provides an overview of the current knowl-
edge on epidermal SCs in the HF, describing their essen-
tial characteristics and the control of follicle SCs fate,
their role in tumorigenesis and alopecia, as well as their
use in tissue engineering.
Stem Cell Characteristics
SCs have the ability of self-renewal, which means that
they can go through numerous cycles of cells division
while maintaining the undifferentiated state and there-
by preserving or expanding the SC pool. Additionally,
SCs are characterized by their potency to differentiate
into specialized cell types. SC differentiation potential
can be described by five terms, depending on the number
of cell types they can differentiate into: totipotent, pluri-
potent, multipotent, oligopotent and unipotent11. While
embryonic stem cells have totipotent differentiation pro-
perties, most adult stem cells are lineage-restricted (mul-
tipotent) and are generally referred to by their tissue ori-
gin (mesenchymal stem cell, adipose-derived stem cell,
endothelial stem cell etc.)12. Multipotent epidermal SCs,
such as follicular cells, have been shown to be capable of
forming HF, epidermis, and sebaceous gland1,13,14.
The self-renewal and multi-lineage differentiation of
SCs make these cells attractive for regenerative medi-
cine, tissue repair and gene therapy. The key aim of SC
research is defining the factors responsible for induction
of SC commitment during skin and HF development, as
well as those maintaining the »stem-ness« of follicular
SC during development15-17.
Localization and Identification of Hair
Follicle Stem Cells
The epidermis is skin’s outer covering, which protects
us from dehydration and external environmental insults.
The outer layer of the hair follicle is contiguous with the
epidermis. Approximately 5 million follicles that are spread
over the body generate hair in cyclical fashion. The dura-
tion of anagen (the period of hair growth), which varies
from less than 60 to more than several thousand days on
different body sites, determines the length of the hair
shaft. After anagen, the follicle enters a stage of involu-
tion (catagen) and afterwards a stage of rest (telogen),
when the hair that was produced dies but remains an-
chored in the follicle until it is shed during exogen.
Finally, stem cells at the base of the resting follicle, in
an area known as the bulge, proliferate and regenerate a
new lower follicle including the highly proliferative bulb
cells that produce a new hair. After giving rise to the new
hair-producing cells, the stem cells return to a quiescent
state, which is a hallmark of these cells. Although sur-
rounded by highly proliferating epidermal and hair folli-
cle cells, the cells in the bulge rarely undergo mitosis.
The extended state of dormancy is conform with other
stem-like characteristics of these cells, including a pro-
longed lifespan18.
Historically, hair follicle stem cells (HFSC) were be-
lieved to reside in the highly proliferative matrix cellular
compartments19, located in the »secondary germ« at the
base of the telogen hair follicle. It was understood that
the secondary germ moved downward to the hair bulb
during anagen and provided new cells for production of
the hair. At the end of anagen, the secondary germ was
thought to move upward with the dermal papilla during
catagen to come to rest at the base of telogen follicle. The
notion of stem cell movement during follicle cycling was
brought into question when Cotsarelis et al.20 identified
a population of long-lived presumptive stem cells, by ad-
ministration of nucleotide analogs (pulse) followed by a
chase period, which resulted in the presence of Label Re-
taining Cells (LRC) in an area of the follicle surrounding
the telogen club hair, called the bulge, suggesting that
bulge cells are more quiescent than the rest of the epider-
mal cells. Afterward, Lyle et al.21 localized LRCs to the
human HF bulge.
The bulge consists of a subpopulation of outer root
sheath (ORS) cells located in the mid-portion of the folli-
cle where the arrector pili muscle attaches to the HF, and
marks the lower end of the »permanent« portion of the
follicle20. The bulge area was already described in 1876
by Unna, who named the bulge area of the adult follicle
the hair bed (Haarbett), believing that the club hair in
catagen became implanted there and derived additional
growth from it. Stöhr gave it a neutral name »Wulst«
(bulge or swelling). Some papers described it as an area
of marked proliferative activity, but it was fairly unclear
since there were no mitotic figures observed even if other
parts of the follicle contained them. Anyhow, these im-
portant morphological observations portended the char-
acterization of the bulge cells in both mouse and human
follicles as an area containing quiescent cells important
for cell cycling13,20–23.
Besides slow-cycling as one of the key features repre-
senting the SCs, there are also other properties of bulge
SC to be investigated. Isolation of living bulge cells is re-
quired in clinical applications such as regenerative medi-
cine and gene therapy. Although morphology based man-
ual micro-dissection has been successfully used to isolate
bulge cells from HF24,25, this technique is time-consum-
ing and requires profound experience and skill, as well as
inadequate to ensure the purity of isolated cells. There-
fore, the research of HFSCs had been delayed until the
identification of bulge cell molecular markers such as
keratin 15 (K15)23 and CD3426. Adult transgenic mice
that carry the enhanced green fluorescent protein (EFGP)
under the control of K15 promoter form the basis for the
successful isolation of living bulge cells using fluores-
cence-activated cell sorting (FACS)23. K15 expression in
human bulge cells was first described by Lyle et al.21. K15
mRNA and protein are reliably expressed at high levels
in the bulge, but lower levels of expression can be present
in the basal layers of lower follicle ORS and the epider-
mis, so the use of K15 expression as a sole criterion for
defining a bulge cell is not advisable21,27. K15 expression
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in the epidermis is prominent in neonatal mouse and hu-
man skin but decreases with age27,28. The expression of
CD34, as first described by Trempus et al.26, represents
the most specific marker for mouse HF bulge cells and is
a valuable tool for bulge cell isolation14. CD34 is, how-
ever, not expressed in the human bulge region. Instead,
CD200 has been identified as a common marker of hu-
man HFSCs and is used for the enrichment of living hu-
man HFSCs. HFSCs are also marked by Sox929, tran-
scription factor 3 (Tcf3)30, LIM homeobox 2 (Lhx2)16, and
leucine-rich G protein-coupled receptor 5 (Lgr5)31. How-
ever, these markers are not uniquely expressed by bulge
cells, as they are also expressed on the cells of the hair
germ and lower ORS of cycling follicles3.
Tumbar et al.32 established the gold standard for de-
tecting SCs in the epidermis by isolating HFSCs using
the LRC technique. They engineered a mouse expressing
histone H2B-green fluorescent protein (H2B-GFP), which
can be turned off when tetracycline is administered into
the animal’s diet (Tet-off system). Keratin 5 (K5) pro-
moter controls the expression of a tet repressor-VP16
transgene, which leads to the expression of H2B-GFP in
the epidermis until 4 weeks of age. At this point, tetracy-
cline is administered for 4 weeks so that the dividing cells
dilute out the label and differentiating cells are shed
from the skin. This leaves only the slow-cycling bulge
cells detectable as H2B-GFB LRCs, and being easily iso-
lated by FACS32.
In addition to epidermal SCs, there are also other types
of SCs that reside in HF: melanocyte SCs in the bulge
area wall, and mesenchymal SCs present in the dermal
papilla and dermal sheath surrounding the HF33,34.
The localization of HFSCs in the bulge area also gives
an illustrative explanation on the differences between per-
manent and reversible hair loss alopecias. In cicatricial
alopecias (lichen planopilaris and discoid lupus erythe-
matosus), inflammation involves the superficial portion
of the follicle, including the bulge area35,36, suggesting
the damage of SCs necessary for the HF regeneration.
The inflammatory injury of alopecia areata, however, in-
volves bulbar region of the HF that is composed of bulge
cell progeny36,37. Although the bulbar area is immediate-
ly responsible for hair shaft production and its destruc-
tion leads to hair loss, the bulge area in this case remains
intact, and a new lower anagen follicle and subsequent
hair shaft can be produced.
In Vitro Assessment of the Bulge Cells’
Proliferative Potential
Since stem cells are responsible for continual renewal
of the tissue, they are supposed to possess a high proli-
ferative capacity. Approximately 5% of adult epidermal
basal cells are shown to have a »holoclone« phenotype
characterized by high proliferative capacity and low level
of terminal differentiation, and these cells are thought to
represent stem cells38. Another indicator of proliferative
capability is colony-forming efficiency (CFE; colonies per
number of cells plated), which correlates to the number
of the stem cells in a tissue24,39.
In order to determine the clonogenic potential of
bulge cells, Barrandon et al.38 dissected the skin epider-
mis into fragments and cultured the cells originating
from these different epidermal regions in vitro. Bulge
cells gave rise to more holoclones than the epidermal
cells coming from other regions, suggesting that bulge
cells, although quiescent in vivo, present a much greater
proliferative potential during in vitro culture25,38. Also,
more recent studies23,26 showed that isolated bulge cells
formed larger and more numerous colonies than non-
-bulge basal keratinocytes. However, Blanpain et al.40 re-
ported that, although majority of holoclones originate
from the bulge in the adult mouse while basal epidermis
did not form any holoclones, both populations had simi-
lar CFE. The inconsistence of this method may be solely
due to the fact that the bulge is enriched by stem cells,
while the basal epidermis contains stem, transient am-
plifying and even differentiated cells, so a higher per-
centage of holoclones from the bulge is anyhow expected14.
Multipotency of the Bulge Cells
If the HFSCs are located in the bulge, then it is ex-
pected that these cells should give rise to all of the lower
hair follicle epidermal cell types14. When bulge cells were
transplanted onto immunodefficient mice, bulge cells can
differentiate into all cell lineages of the skin epidermis
including HF, interfollicular epidermis and sebaceous
glands, demonstrating that bulge region contains SCs
with different potential lineages13. Later on, Blanpain et
al.40, as well as Claudinot et al.41 confirmed the multi-
potency of bulge cells by using clonal analysis and show-
ing that the progenies of one single bulge SC can recon-
stitute all the epidermal lineages of the skin epidermis.
Fate mapping studies also indicated that bulge cells are
multipotent SC, which means that they are able to give
rise to all cells of the hair follicle, sebaceous gland and
intefollicular epidermis23,32,42.
A common finding of these studies was that there is a
little if any contribution of bulge SC to the maintenance
of intefollilular epidermis during the adult skin homeo-
stasis, suggesting that unipotent progenitors ensure re-
newal of interfollicular epidermis23,43. However, upon
wounding, bulge SC are activated, and migrate rapidly
toward the skin lesions and participate actively in the re-
pair of epidermis22,42,44,45. Once the epidermal repair is
completed, the flux of bulge cells stops, and the bulge
cells that had migrated in the interfollicular epidermis
gradually disappear overtime42.
In addition to the bulge and interfollicular SCs, there
are also other types of epidermal progenitors recently de-
scribed that participate in the homeostasis of other epi-
dermal compartments such as sebaceous gland and the
infundibulum, the portion of epidermis connecting the
HF to the interfollicular epidermis. Experiments per-
formed by Ghazizadeh et al.46 suggested the existence of
unipotent sebaceous lineage progenitors, while Horsley
et al.47 identified rare cells located at the juncture be-
tween HF and sebaceous gland able to give rise to the en-
tire sebaceous gland. These findings show that sebaceous
glands homeostasis, just like homeostasis of interfolli-
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cular epidermis, can be maintained by the presence of
unipotent progenitors. In contrast to these, Nijhof et al.48
identified the multipotent MTS24 expressing cells in a
region located above the bulge but below sebaceous gland,
within the upper isthmus, which are able to give rise to
all three epidermal lineages48,49. Furthermore, consider-
ing the presence of other, nonepithelial SCs in the HF,
HF bulge SCs can also differentiate into neurons, glia,
smooth muscle cells, and melanocytes in vitro, which
provides an effective and accessible autologous source of
SCs50.
Regulation of the Bulge Stem Cells’
Activations and Maintenance –
The Bulge as a Stem Cell Niche
All SC populations exist in specific anatomic loca-
tions, so-called niches, where they are protected from de-
pletion and kept in the microenvironment of specific
growth factors, which regulate their activity. So far, HF
bulge area is now the best characterized SC niche in the
skin.
The evidence acquired from the gene profiling23,32,51
and immunohistological analyses52 prove that the bulge
region HFSCs enjoy a relative immune privilege, primar-
ily due to down-regulation of MHC class I molecules and
the local up-regulation of potent immuno-suppressants
such as a-MSH and CD20053. This immune privilege pre-
sumably protects the HF epithelial stem cell reservoir
from auto-aggressive immune attack, whereas a loss of
bulge immune privilege may play a central role in the
pathogenesis of cicatricial alopecias52.
Also, the activation and self-renewal of HFSCs should
be tightly regulated to maintain HF and epidermal ho-
meostasis. HFSCs isolation and microarray analysis of
multiple gene expression were used to investigate the
molecular signatures of the HFSCs that are considered
to participate in controlling the fate of SCs3.
Gene expression analysis in the telogen HFSCs and
interfollicular epidermal proliferative basal layer cells re-
vealed that genes that participate in maintaining the
resting and undifferentiated state of HFSCs were up-reg-
ulated – components of the bone morphogenetic pro-
tein/transforming growth factor-b (BMP/TGF-b) signal-
ing pathway, including latent TGF-b binding protein 1
(Ltbp1), Ltbp2, Ltbp3, TGF-b2, Gremlin, and the phospho-
rylation of Mothers against dpp homolog 1 (phospho-
-Smad1) and phospho-Smad223,32. Additional upregulated
genes included inhibitors of the Wnt/b-catenin signaling
pathway, such as Tcf3, Tcf4, Dickkopf-related protein 3
(Dkk3), secreted frizzled-related protein 1 (SFRP1), dis-
abled-2 (Dab2), and C-terminal banding protein 2 (Ctbp2).
In contrast, those genes involved in the regulation of HF
proliferation were down-regulated in HFSCs23,32. These
findings have elucidated, at least in part, how the HFSCs
are maintained in a quiescent and undifferentiated state
in adult mouse HFs.
So far, the Wnt/b-catenin and BMP/TGF-b signaling
pathways are considered to be the most important regu-
lators of HFSC. Wnt signaling is important for activating
HFSCs and has a sequential role in regulating HFSC
lineages42,54, whereas b-catenin is required for SC main-
tenance and niche biology, and its activation is essential
for promoting the transition of quiescent HFSCs into
proliferating transit amplifying cells that terminally dif-
ferentiate along the hair cell lineage55–60. On the other
hand, inhibitory effect of BMP/TGF-b signaling pathway
mediates the maintenance of the special quiescent na-
ture of HFSCs61–65.
BMP signaling inhibits SC activation, at least partly,
by inhibiting the nuclear localization of b-catenin65,66.
Activation of the Wnt pathway and inhibition of the
BMP pathway are likely to converge to regulate bulge SC
activation, which is dependent on b-catenin stabilization,
the junction point of both signaling pathways. Addi-
tionally, BMP signaling may also coordinate with tran-
scription factor of activated T cells c1 (NFATc1), a tran-
scription factor specifically expressed in HF bulge cells,
that favors SC quiescence partly through the trans-
criptional repression of the cell cycle regulatory gene
cyclin dependent kinase 4 (CDK4)32,67. Nonetheless, the
exact mechanism by which BMP signals are coordinated
with TGF-b and their antagonists in order to regulate the
activation, proliferation and maintenance of HFSCs needs
further research and clarification.
Hair Follicle Stem Cells as a Hot Target for
Regenerative Medicine
Due to their location at the body surface, HFs consti-
tute a promising source of readiliy accessible adult SCs68.
The development of molecular techiniques that enabled
isolation and culture of autologous adult epidermal, me-
senchymal and neuronal HFSCs from a patient’s own
HFs opened a spectrum of therapeutic perspectives for:
1) treatment of third-degree burn victims, 2) promotion
of the healing of large, chronic leg ulcers, 3) de novo gen-
eration of new human hair follicles and 4) gene therapy
strategies53. Gene therapy would have a role in treat-
ment of inherited structural and enzymatic skin defects
(in example epidermolysis bullosa), where genetically en-
gineered and modified, fully functional autologous HFSCs
would be transplanted in order to gradually replace de-
fective tissue69,70. Also, melanocytic SCs could be used to
prevent or revert heir graying, or in treatment of epider-
mal depigmenting disorders like vitiligo. On the other
hand, even permanent removal of cosmetically unwanted
hair could be approached by targeted damage of SC re-
generative capacity of the HF53.
Although the knowledge about HFSCs has substan-
tially increased in recent years, many unanswered ques-
tions remain and the whole field is still kept in the do-
main of preclinical research. By now, only interfollicular
basal layer epidermal SCs are in clinical use for treat-
ment of patients suffering from severe burnt injuries.
The method was described in 1979 by Green et al.71,
when they found that human epidermal SCs have an
enormous proliferating potential, discovering that only
few in vitro cultured cells can regenerate, differentiate
and reform a functional skin barrier that can be trans-
planted onto the severely burnt patients. This method is
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very powerful since it allows transplantation of much
larger pieces of autologous skin that it is permissible by
the classic autologous skin grafting. The limitations of
this method are the time needed to grow the confluent
epithelial sheets in vitro and the huge cost of the treat-
ment. Also, the grafted skin grown by this method does
not contain HFs and sweat glands. With the intention of
achieving HF regeneration in grafted epidermal sheets
coming from cultured epidermal SCs, dermal papilla cells
need to be co-transplanted in order to stimulate epider-
mal SCs to adopt HF fate72. The underlying reason is
that HF morphogenesis and regeneration is much more
complex since its development, like in all ectodermal or-
gans (teeth, salivary glands), depends on the reciprocal
epithelial-mesenchymal interactions between epidermal
SCs and mesenchymal SCs in dermal papilla73.
So in order to achieve the HF regeneration in the hair
cycle, it is essential to regenerate various stem cells and
their niches74,75. Many studies attempted to develop tech-
nologies to renew the variable lower region of the hair
follicle72,76, to achieve de novo folliculogenesis via re-
placement with HF-inductive dermal cells77, and to direct
the self-assembly of skin-derived epithelial and mesen-
chymal cells78–83. Nakao et al.84 reported that a bio-
engineered HF germ, reconstituted from embryonic folli-
cle germ-derived epithelial and mesenchymal cells can
generate a bioengineered HF and shaft. The latest study
of Toyoshima et al.9 demonstrated fully functional ortho-
topic hair regeneration via the intracutaneous transplan-
tation of bioengineered hair follicle germ. Also, Asakawa
et al.8 proved fully functional regeneration using ecto-
pically bioengineered HFs transplanted via the FUT
method that are practical for clinical therapies. The
bioengineered hair had the correct structures of the nat-
urally occurring hair follicle and shaft, and it formed
proper connections with surrounding host tissues (epi-
dermis, arrector pili muscle and nerve fibres). The bio-
engineered HFs showed full functionality, including the
ability to undergo repeated hair cycles through the rear-
rangement of various stem cell niches, as well as respon-
siveness to the neurotransmitter acetylcholine (ACh).
This study hence demonstrated the potential for not only
hair regeneration therapy but also the realization of
bioengineered organ replacement using adult somatic
stem cells. The studies of Toyoshima et al. and Asakawa
et al.8,9 provided novel evidence of fully functional hair
follicle regeneration through the rearrangement of vari-
ous stem cells and their niches in bioengineered hair fol-
licles, and gave a substantial contribution to the develop-
ment of bioengineering technologies that will enable
future regenerative therapy for hair loss caused by injury
or by diseases such as alopecia and androgenic alopecia.
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NAPREDAK U POLJU ISTRA@IVANJA MATI^NIH STANICA DLA^NOGA FOLIKULA
S A @ E T A K
Ko`a odrasle osobe zadr`ava sposobnost regeneracije, s obzirom da se trajno obnavlja tijekom odrasle dobi, a dla~ni
folikuli neprekidno prolaze kroz ciklus rasta i degeneracije. Istra`ivanje epidermalnih mati~nih stanica i in`enjering
ko`noga tkiva je polje u kojemu je u zadnje vrijeme do{lo do zna~ajnih napredaka kako u bazi~nim, tako i u klini~kim
istra`ivanjima. Napretci bazi~nih istra`ivanja uklju~uju mogu}nost istra`ivanja epidermalnih mati~nih stanica in vivo,
prepoznavanje nezavisnih interfolikularnih epidermalnih mati~nih stanica, bolju sposobnost analize pojedinih dioba
mati~nih stanica, kao i nedavno uspjelu regeneraciju dla~noga organa putem transplantacije bioin`enjeringom stvorene
dla~ne jedinice u mi{eva (FUT, prema engl. follicular unit transplantation). Napredak u klini~kim istra`ivanjima uklju-
~uje prepoznavanje va`nosti epidermalnih mati~nih stanica u cijeljenju rane, kao i u genskoj terapiji nasljednih bolesti
ko`e, kao {to je npr. bulozna epidermoliza. Istra`ivanje folikularnih mati~nih stanica zapo~eto je identifikacijom epider-
malnih mati~nih stanica kao nijemih stanica koje zadr`avaju biljeg (LRC, prema engl. label retaining cells) u izbo~ini
dla~noga folikula. Istra`ivanje ovih stanica ubrzano se razvilo nakon utvr|ivanja specifi~nih molekularnih biljega sta-
nica izbo~ine dla~noga folikula, kao {to su keratin 15 (K15) i CD34 u mi{eva, te CD200 u ljudi, jer su oni omogu}ili
izolaciju i utvr|ivanje zna~ajki stanica izbo~ine iz dla~nih folikula. U ovome ~lanku donosimo pregled dosada{njih spo-
znaja o folikularnim epidermalnim mati~nim stanicama, opisuju}i njihove temeljne zna~ajke, na~in regulacije njihova
usmjeravanja, ulogu u alopeciji, te mogu}nosti njihova kori{tenja u tkivnom in`enjeringu.
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